Cooper Co stock analysis
Cooper Co (0I3I) Share Price & Analysis
0I3I Stock Chart & Stats
- Day’s Range
- $62.07 - $63.60
- 52-Week Range
- $51.02 - $89.11
- Previous Close
- $62.88
- Volume
- N/A
- Average Volume (3M)
- 956
- Market Cap
- $11.77B
- Enterprise Value
- $16.38B
- Total Cash (Recent Filing)
- $154.70M
- Total Debt (Recent Filing)
- $2.54B
- Price to Earnings (P/E)
- 21.2
- Beta
- 1.10
- Next Earnings
- Dec 03, 2026 (Est.)
- EPS Estimate
- 1.07
- Last Dividend Ex-Date
- Jul 26, 2023
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Sustained top-line growth indicates continued demand across Cooper’s women’s health and vision businesses. A growing revenue base can support investment in products, commercial coverage and innovation, while improving the company’s ability to absorb operating cost pressure over the next several quarters.
Conservative Balance Sheet
Moderate and improving leverage gives Cooper financial flexibility to fund research, commercial expansion and targeted capital returns without relying heavily on additional borrowing. Equity growth and manageable debt also improve resilience if margins or demand remain uneven during the next two to six months.
Fertility Growth Drivers
Fertility demand is supported by structural demographic, access and policy trends rather than only temporary purchasing patterns. Cooper is also reporting market-share gains, clinic wins, genomics demand and broader product adoption, which may reinforce its position as treatment utilization expands.
Bears Say
Weak Cash Conversion
The sharp TTM deterioration in operating and free cash flow weakens earnings quality and reduces internally generated funds available for investment or capital returns. Unless cash conversion recovers, working-capital or spending pressure could constrain flexibility despite the company’s otherwise manageable leverage.
Operating Margin Compression
Lower operating profitability shows that revenue growth is not currently translating efficiently into earnings. Higher costs or other operating pressures can limit the benefit of scale, and continued margin weakness would reduce funds available for innovation, commercial expansion and shareholder returns.
Leadership Transition
A sudden CEO departure creates execution and continuity risk while the board conducts a leadership search. Interim oversight may provide stability, but strategic priorities, commercial execution and investor confidence could remain unsettled until a permanent chief executive is selected and establishes a durable plan.
Cooper Co News
0I3I FAQ
What was Cooper Co’s price range in the past 12 months?
What is Cooper Co’s market cap?
When is Cooper Co’s upcoming earnings report date?
How were Cooper Co’s earnings last quarter?
Is Cooper Co overvalued?
Does Cooper Co pay dividends?
What is Cooper Co’s EPS estimate?
How many shares outstanding does Cooper Co have?
What happened to Cooper Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cooper Co?
What is the TipRanks Smart Score and how is it calculated?
Cooper Co Stock Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White
- Employees
- 15,000
- Website
- www.coopercos.com
- Address
- 6101 Bollinger Canyon Road, San Ramon, CA, 94583, US
Cooper Co (0I3I) Earnings & Revenues
0I3I Company Deck
0I3I Earnings Call
Earnings Call SentimentPositive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.
View all GB:0I3I earnings summaries0I3I Net sales Breakdown
- 67.05% CooperVision
- 32.95% CooperSurgical
0I3I Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |















